Moderna(US:MRNA) Financial Modeling Prep·2026-01-20 00:05Group 1 - Moderna, Inc. is a leading biotechnology company known for its mRNA technology, particularly in COVID-19 vaccine development, competing with Pfizer and BioNTech [1] - Citigroup has updated its rating for Moderna to "Neutral," indicating that investors should hold onto the stock, which is currently trading at approximately $41.84 [1][5] - The stock has seen a 6.29% increase, with a daily trading range between $40.55 and $42.30, and a market capitalization of around $16.35 billion [4][5] Group 2 - Investors often focus on stocks that are expected to exceed quarterly earnings estimates, as these can significantly influence stock prices [2] - The Zacks Earnings ESP tool is utilized to identify potential earnings surprises by analyzing recent analyst revisions, which can help investors enhance their returns [3]